首页> 美国卫生研究院文献>Molecular and Clinical Oncology >Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases
【2h】

Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases

机译:胸苷酸合酶在原发性结直肠癌中的表达作为对基于5-氟尿嘧啶和奥沙利铂的肝转移术前化疗反应的预测指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In patients with colorectal liver metastases (CRLM), predictive markers for response to preoperative chemotherapy are lacking. The aim of the present study was to evaluate the expression of thymidylate synthase (TS) and excision repair cross-complementation group 1 (ERCC1) as predictive markers in CRLM. A total of 24 patients with CRLM were included in this study. Tumor response was evaluated using the tumor regression grade (TRG) and Response Evaluation Criteria in Solid Tumors (RECIST) methods. TS and ERCC1 expression in paired CRLM and primary lesions were assessed by immunohistochemistry. We analyzed correlations between i) the response to preoperative chemotherapy evaluated by TRG and RECIST, ii) TS and ERCC1 expression and the response evaluated by TRG and RESICT, and iii) TS and ERCC1 expression in matched pairs of primary tumor and CRLM. The preoperative chemotherapy response evaluated by TRG and RECIST was significantly associated (P=0.0005). The response based on RECIST criteria and TRG was significantly associated with TS expression in the primary tumor (P=0.0272, and P=0.0137, respectively). No correlations were detected between marker expression in the primary tumor and in CRLM for either TS or ERCC1 (P=0.371 and P=1.00, respectively). Our data suggested that TS expression in the primary tumor is a predictive marker of preoperative chemotherapy response in CRLM based on both TRG and RECIST methods.
机译:在结直肠肝转移(CRLM)患者中,缺乏对术前化疗反应的预测指标。本研究的目的是评估胸腺嘧啶合酶(TS)和切除修复交叉互补组1(ERCC1)在CRLM中的表达。本研究共纳入24例CRLM患者。使用肿瘤消退等级(TRG)和实体肿瘤反应评估标准(RECIST)方法评估肿瘤反应。通过免疫组织化学评估成对CRLM和原发灶中TS和ERCC1的表达。我们分析了i)用TRG和RECIST评估对术前化疗的反应,ii)TS和ERCC1表达与用TRG和RESICT评估的反应之间的相关性,以及iii)TS和ERCC1在配对的原发肿瘤和CRLM对中的表达之间的相关性。 TRG和RECIST评估的术前化疗反应显着相关(P = 0.0005)。基于RECIST标准和TRG的反应与原发性肿瘤中TS的表达显着相关(分别为P = 0.0272和P = 0.0137)。对于TS或ERCC1,在原发性肿瘤和CRLM中的标志物表达之间未检测到相关性(分别为P = 0.371和P = 1.00)。我们的数据表明,基于TRG和RECIST方法,原发性肿瘤中TS的表达是CRLM术前化疗反应的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号